Blockchain Registration Transaction Record

Propanc Biopharma Raises $4M to Advance Cancer Stem Cell Treatment

Propanc Biopharma closes $4M public offering to fund cancer stem cell treatment research targeting pancreatic, ovarian & colorectal cancers through novel proenzyme therapy.

This development matters because cancer remains one of the leading causes of death worldwide, with metastatic disease responsible for the majority of cancer-related fatalities. Propanc Biopharma's approach targeting cancer stem cells represents a promising frontier in oncology, as these cells are often resistant to conventional therapies and drive tumor recurrence. The successful funding round enables continued research into a treatment that could potentially prevent cancer from spreading and returning, addressing a critical unmet medical need. For patients battling pancreatic, ovarian, and colorectal cancers—some of the most aggressive and difficult-to-treat malignancies—this research could lead to more effective treatment options and improved survival rates. The investment also signals growing confidence in innovative cancer therapies that move beyond traditional chemotherapy approaches.